WuXi AppTec Acquires US-Based Pharmapace

Pharmapace will become a wholly-owned subsidiary of WuXi Clinical and will continue to focus on growing its core biometrics competences.

AsianScientist (Jun. 12, 2019) – WuXi AppTec, a global pharmaceutical and medical technology platform company, has acquired Pharmapace, a US-based clinical research services company.

Founded in 2013 in San Diego, US, Pharmapace provides a full range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration and medical writing. Its clients hail from North America, Europe and Asia. With this acquisition, WuXi Clinical—the clinical CRO arm of WuXi AppTec—expands its biometrics capabilities in the US and Europe.

“This combination now allows us to leverage WuXi AppTec’s vast resources to offer customers a truly global solution from preclinical development to clinical development and regulatory submission,” said Dr. Larry Shen, president and CEO of Pharmapace.

Mr. Edward Hu, Co-CEO of WuXi AppTec, added that the acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities, and lays the foundation for the creation of an integrated global biometrics service platform to provide customers with seamless biometrics services globally.

“Together, we are able to shorten time-to-market of new drugs and to achieve the dream that ‘every drug can be made and every disease can be treated’,” said Hu.


Source: WuXi AppTec; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist